Background: Use of weekly single agent cisplatin (CDDP) in moderate doses (30-40 mg/m2) is now a standard. Concomitant chemoradiotherapy with cisplatin and 5FU with weekly gaps may offer a benefit with less severe toxicity. Taking a cue from the available data on this approach and our own experience with this regime, we used it for the treatment of Locally Advanced Head and Neck Cancer and present an audit of the same.Objective: To assess the efficacy in terms of overall response of head and neck cancer patients receiving concurrent chemo-radiation.